VectorB2B is a non-profit association created in January 2019 and awarded with the title of Collaborative Laboratory (CoLAB) by the Fundação para a Ciência e a Tecnologia, the Portuguese public agency that supports science, technology and innovation.
The stakeholders are a strong and complementary set of renowned academic and industrial partners within the Portuguese health sector. Together, we form a robust asset of knowledge and innovation.
VectorB2B provides highly qualified services of drug discovery and development from the bench to bedside (B2B).
It gathers the scattered capacities of the academic and industrial stakeholders within the Portuguese Health Sector to provide integrated services in drug discovery and screening, project design and implementation, pre-clinical and clinical scientific management, process development and GMP manufacturing.
VectorB2B is your partner for cost-efficient, rapid and strategic drug discovery & development.
Our specialists develop the best process for your needs, including galenic formulation and biologic cultures – from lab scale to GMP certified 50L disposable bioreactor
Let us support you in the fight against COVID-19 with our antibody development services and our clinical trial expertise or testing your molecules in neutralization assays in a P3 setting or in vivo models
VectorB2B stakeholders are a strong and complementary set of academic and industrial partners renowned in the Health Sector in Portugal. Together, we form a robust platform of knowledge and innovation, providing cutting-edge technology and expertise, adding value to our customers.
VectorB2B aims to enable the discovery and development of new therapies by offering a range of comprehensive services and expertise to clients in the biotech, pharmaceutical and academic sector. We earn our clients’ trust by offering the best services, tailored to your specific needs.
VectorB2B is committed to providing clear and transparent information regarding animal studies and animal care and welfare standards carried out in our partner institutions and therefore contribute to public clarification and a conscious and informed position in this debate of general interest. In January 2022, VectorB2B signed the Transparency Agreement on Animal Research in Portugal, an initiative supported by the Portuguese scientific community in collaboration with the European Animal Research Association (EARA) to promote a more consistent approach to communicating the scientific, ethical, and moral justifications for studies involving animals in Portugal. We acknowledge that it is not yet possible to completely replace the use of animals in drug discovery and development. Without the help of animals, most medicines, antibiotics, vaccines, and surgical techniques applied in human and veterinary medicine would not exist. Therefore, VectorB2B strongly endorses and encourages the application of the 3Rs principle: replacement of animals with alternative non-animal methods whenever possible, reduction of the number of animals used, and refinement of procedures to improve animal welfare.
Expertise and services from strong academic and industrial partners. Customer keeps full IP rights.
Business and scientific counseling strategy. Flexible design adjusted to customer needs.
Project management and ongoing, monitoring and reporting.
Drug discovery and development services including pre-clinical studies, contract manufacturing and clinical trial solutions.
The combination of CDMO/CRO services leads to cost and time-efficient solutions.
We will monitor progression of service, collaborating closely with you to ensure successful work completion, deliverable submission and reporting.
Office:
Avenida da Liberdade, 258, 6º
1250-149 Lisboa, Portugal
+351 210 976 863
© 2024 digital connection | All rights reserved | Privacy policy| Data Privacy Contact Form
